Mylan’s EpiPen has been the most recent of a series of pharmaceutical pricing increases to invoke a strong public reaction. How will all of the push against rising pharmaceutical prices affect R&D-focused companies’ ability to provide innovative, life-changing new therapies to patients? Read more here. (Forbes, 9/13/16)
You are here: / / Is EpiPen Pricing Threatening to Impede Innovation?